Search Results

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada

Nanomerics Ltd., a private speciality pharmaceutical company announced that the Company had been granted patent protection in Canada for the ocular use of its Molecular Envelope Technology drug delivery system.

April 13, 2023

·

4 min read

Nanomerics Awarded an MHRA Innovation Passport for OC134

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had received an Innovation Passport from the UK Medicines and Healthcare Products Regulatory Agency for its lead asset - OC134.

August 31, 2022

·

3 min read

Meet Nanomerics CSO in Montreal This Summer - Nanomerics CSO to Give Plenary Lecture at Controlled Release Society Annual Meeting and Expo in Montreal on 13th July 2022

Nanomerics Ltd ., a private speciality pharmaceutical company, today announced that Nanomerics’ Chief Scientific Officer would be giving a plenary lecture at the Controlled Release Society Annual Meeting and Expo on Wednesday 13th  July 2022. 

July 11, 2022

·

3 min read

Nanomerics CSO Made Honorary Fellow of the Royal Society of Chemistry

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the company’s Chief Scientific Officer, Professor Ijeoma F. Uchegbu, had been made an Honorary Fellowship of the UK’s Royal Society of Chemistry.

July 20, 2022

·

3 min read

Business

Nanomerics Expands and Moves to New Laboratories

Nanomerics Ltd., a private speciality pharmaceutical company and University College London spin out, announced that the Company had invested significantly in its operations, and moved to new laboratories and offices in North London.

February 17, 2022

·

4 min read

Business

Nanomerics Announces Quotient Sciences as its Clinical Trials Partner

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.

March 28, 2022

·

4 min read

Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)

Nanomerics Ltd., a private speciality pharmaceutical company, announced the receipt of a further milestone payment on agreeing the expansion of its anti-viral spray licence to Virpax Pharmaceuticals.

March 22, 2022

·

3 min read

Better Brain Medicines - Nanomerics Announces Patents Granted in the US, Europe and Japan on the Nose to Brain Use of its Molecular Envelope Technology

Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had been granted patent protection in multiple jurisdictions for brain delivery applications of its Molecular Envelope Technology.

March 14, 2022

·

3 min read

Policy

Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology

Nanomerics Ltd., a world leader in molecular engineered delivery technologies, announced the Company had been granted patent protection in multiple territories for the use of its Molecular Envelope Technology for ocular applications.

May 24, 2021

·

3 min read

Business

Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses

Virpax today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray

August 24, 2020

·

3 min read